Cabell Christopher 4
4 · Inhibikase Therapeutics, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Cabell Christopher
President & Head of R&D
Transactions
- Award
Stock Option (Right to Buy)
2026-01-05+900,117→ 900,117 totalExercise: $2.01Exp: 2036-01-05→ Common Stock (900,117 underlying)
Footnotes (1)
- [F1]The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.